#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)October 15, 2026 - 18:00 CEST

 

 #### Novartis Pavillon

 

 

 

 ![title-behind-the-science-organoids](/sites/campus_com/files/styles/crop_freeform/public/2026-09/BtS_Organoids_5_2026_4zu5_E.png.webp?itok=nEch-mVe "title-behind-the-science-organoids")

 

“Mini-Organs, Great Hope: How Organoids Are Transforming Medicine”

How can we better understand diseases without experimenting directly on humans? One answer comes from so-called organoids: tiny tissues grown from human cells that can surprisingly replicate many characteristics of real organs. They give researchers a new way to study how diseases develop and how future therapies can be created.

In this talk, you will learn how such models are produced and why they have revolutionized biomedical research in recent years. Using current examples, we will show how organoids are used to better understand human biology and develop new medicines. At the same time, we will look at the possibilities and limitations of this technology.

What role does artificial intelligence play in this? And how could biological models and AI together shape the future of research? The talk is aimed at anyone who wants to know how modern science is trying to shape the medicine of tomorrow.

This event will be held in English

Please register [here](https://ticketing.pavillon.novartis.com/?op=booking&id=136)

**Maurice Kahnwald:**

After studying biomedicine and biochemistry in Mannheim, Germany, Maurice Kahnwald devoted four years to his doctoral research: he developed an organoid model of the human intestine and investigated the stem cell populations it contains. His current work builds on this foundation.

For the past two years, he has served as project leader of the Applied Tissue Models Center (ATMC) at the Friedrich Miescher Institute in Basel. There, he coordinates collaborations with partners from academia and industry, drives the automation of laboratory processes, and helps shape the further development of innovative tissue models.

An important part of this work is also training: he is actively involved in educating the next generation of scientists in the use of these new model systems.

**Philipp Hoppe:**

Philipp Hoppe is a laboratory head at Novartis in Basel. For nearly 11 years, he has worked on making human disease models useful for the development of new medicines. After studying and completing his doctorate in stem cell biology in Munich, as well as a research stay at ETH Zurich, he joined Novartis.

Today, he combines modern genomics, automation, and innovative tissue models to better understand disease mechanisms and enable new therapeutic approaches.

At the Applied Tissue Models Center (ATMC), he works together with partners from research and technology to develop forward-looking models for biomedical research.